Last reviewed · How we verify
MABp1
At a glance
| Generic name | MABp1 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Benefit of Bermekimab in Patients With Systemic Sclerosis (PHASE2)
- A Study of Bermekimab in Patients With Hidradenitis Suppurativa (PHASE2)
- A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (PHASE3)
- A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes (PHASE2)
- A Pharmacokinetic Study of MABp1 in Healthy Volunteers (PHASE1)
- A First in Man Study of MABp1 in Patients With Advanced Cancers (PHASE1)
- MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MABp1 CI brief — competitive landscape report
- MABp1 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI